{"id":"W4405047896","doi":"10.1182/blood-2024-194550","title":"Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Samsung; Italfarmaco; Scheme for Promotion of Academic and Research Collaboration; Swedish Orphan Biovitrum; Servier; Department of Health, Government of Western Australia; Astellas Pharma; CTI Biopharma; F. Hoffmann-La Roche; Incyte; Ascentage Pharma; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Gilead Sciences; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Systemic mastocytosis; Medicine; Apex (geometry); Clinical trial; Phases of clinical research; Internal medicine; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001793259,0.001690533,0.002426695,0.0003255916,0.000355682,0.001549218,0.001043161,0.00169566,0.008038673],"category_scores_gemma":[0.001342355,0.0005347686,0.001538069,0.0003517921,0.0007303572,0.001419919,0.0005356016,0.004101945,0.001736733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008776347,"about_ca_system_score_gemma":0.001467259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005445794,"about_ca_topic_score_gemma":0.001837795,"domain_scores_codex":[0.9996371,0.0001429424,0.00001911213,0.00006702603,0.00005090146,0.00008297799],"domain_scores_gemma":[0.9993168,0.0001024614,0.0001416091,0.00005164608,0.00009477776,0.0002926337],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.70486,0.03567211,0.007585661,0.003853105,0.003107506,0.0008763063,0.0005856563,0.004768793,0.03490276,0.002176676,0.04438486,0.1572267],"study_design_scores_gemma":[0.8686004,0.1082401,0.006566735,0.0001516315,0.0006430923,0.0006680756,0.0001004964,0.0023498,0.001430535,0.0008954553,0.01029643,0.00005709722],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9430759,0.01681359,0.002739995,0.004445842,0.0008347049,0.01023771,0.01049871,0.0007026942,0.01065081],"genre_scores_gemma":[0.9357021,0.01165152,0.006551899,0.007006086,0.0008335066,0.0116482,0.0166556,0.000160076,0.009790981],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008038673,"threshold_uncertainty_score":0.02689201,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03009633090862173,"score_gpt":0.3280439072700009,"score_spread":0.2979475763613791,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}